Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study — Laila Stærk (2017) | RDL Network
Standard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.
Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Professor Gregory Lip
Laila Stærk, Emil Loldrup Fosbøl, Professor Gregory Lip, Morten Lamberts, Anders Nissen Bonde, Christian Torp‐Pedersen, Brice Ozenne, Thomas Alexander Gerds, Gunnar Gislason, Jonas Bjerring Olesen
Discussion(0)
No comments yet. Be the first to comment.